Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | S1PR1 | P21453 | 14/20 | 0.61 |
| ▸ | S1PR5 | Q9H228 | 14/20 | 0.61 |
| ▸ | S1PR4 | O95977 | 13/20 | 0.61 |
| ▸ | S1PR3 | Q99500 | 10/20 | 0.61 |
| ▸ | PTGER4 | P35408 | 1/20 | 0.42 |
| ▸ | PLK1 | P53350 | 1/20 | 0.39 |
| ▸ | FFAR1 | O14842 | 2/20 | 0.38 |
| ▸ | FFAR4 | Q5NUL3 | 2/20 | 0.38 |
| ▸ | ADAMTS5 | Q9UNA0 | 1/20 | 0.36 |
| ▸ | APOB | P04114 | 1/20 | 0.36 |
| ▸ | MTTP | P55157 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4300201 | 0.93 | S1PR1 (0.57) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089810 | 0.87 | S1PR5 (0.70) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089813 | 0.85 | S1PR1 (0.68) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089817 | 0.85 | S1PR1 (0.68) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL5794959 | 0.85 | S1PR1 (0.59) | S1PR1S1PR5S1PR4S1PR3 | |
| SCHEMBL14114786 | 0.85 | S1PR1 (0.67) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089831 | 0.85 | S1PR1 (0.67) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089824 | 0.85 | S1PR1 (0.67) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089809 | 0.85 | S1PR1 (0.67) | S1PR1S1PR5S1PR4S1PR3PTGER4 | |
| SCHEMBL14089710 | 0.84 | S1PR1 (0.58) | S1PR1S1PR5S1PR4S1PR3PTGER4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | claimed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | BIO-PROJET (FR) | 2009-10-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090264469-A1 | NOVEL DICARBOXYLIC ACID DERIVATIVES | S1PR2, S1PR1, S1PR5 | S1PR1 2/4885S1PR5 3/4885S1PR4 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.